Menopause Hormone Therapy (HRT) in Sandy, UT

Bioidentical hormones in Sandy: what it means

Behind the label "bioidentical hormone replacement therapy" is a plain idea: a hormone whose structure matches the body's own. Two hormones used in menopause care fit it exactly, estradiol and micronized progesterone. FDA-approved versions of both are sold by prescription at retail pharmacies.

Only 11 OB-GYNs list a primary practice address in Sandy in the NPI registry. For 94,723 residents that is 11.6 per 100,000, under the US 17.8 and below Utah's 15.2. Set against the city's 11,512 women aged 45 to 64, that is one OB-GYN for roughly every 1,050.

Widen the circle and the count grows: 121 in the city or within 10 miles, 271 within 25 miles. For the 1,823,453 people who live within 25 miles, that is 14.9 per 100,000. VevaMD is an online option alongside them: a physician licensed in Utah reviews your intake from Sandy without an office visit, and an OB-GYN you already see stays your doctor.

"BHRT" often means compounded hormones, a cream, a blend such as Bi-Est or a pellet that a pharmacy mixes for one prescription. They are not FDA-approved, which means the FDA cannot assure their safety or effectiveness. The FDA says it has no evidence that compounded "bioidentical hormones" are safe and effective, or more effective than FDA-approved hormone therapy. The National Academies, reviewing them for the FDA in 2020, called their wide use a public health concern.

For women in Sandy, a physician licensed in Utah can prescribe estradiol (pill, patch, cream or vaginal) and progesterone when they fit your history. There are no pellets. The pharmacy that fills VevaMD prescriptions also compounds, so ask your physician whether yours is an FDA-approved product or compounded. Two options are compounded for certain: testosterone cream for women and Bi-Est are not FDA-approved.

A pellet clinic is a different model: it implants a hormone pellet under the skin during a visit, and compounded pellets are not FDA-approved. The Endocrine Society points to a study that found hormone levels well above the expected range in women using them. ACOG's guidance is to prefer FDA-approved menopause hormone therapy to compounded hormones.

Sources: FDA: Menopause · FDA: National Academies study of compounded bioidentical hormones (2020) · Endocrine Society position statement on compounded bioidentical hormones (2019) · ACOG Clinical Consensus No. 6, compounded bioidentical menopausal hormone therapy (2023) · CMS NPPES NPI full file, 2026-10-11